Company
Modalis Therapeutics Corp
Headquarters: Tokyo, Japan
Employees: 20
CEO: Mr. Haruhiko Morita
Market Cap
¥3.63 Billion
JPY as of Jan. 1, 2024
US$25.8 Million
Modalis Therapeutics Corp Categories
Japan Healthcare Drug Manufacturers—Specialty & GenericJapan Healthcare Japan Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies fo genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Modalis Therapeutics Corp has the following listings and related stock indices.
Stock: JPX: 4883 wb_incandescent